HTGF exits Cytena in €30.25m deal

Cellink has acquired the company to expand its technology portfolio and support further expansion in the pharmaceutical industry. The company's technology would also complement Cellink's 3D bioprinting technologies.

Cytena will continue to operate under its own brand and the current management team will continue at the helm.

Previous funding
In 2015, HTGF and private investors made an early-stage investment of €1.1m in Cytena. HTGF and two angel investors then made an investment of €3m in early 2019.

Company
Cytena was spun out from the Institute for Microsystems Technology at the University of Freiburg in 2014. Cytena primarily sells products and services for handling biological cells; it has developed a single-cell dispensing platform that enables pharmaceutical companies to develop antibodies and cell lines. The company is based in Freiburg and employs 24 people, according to LinkedIn.

People
High-Tech Gründerfonds – Lena Krzyzak (senior investment manager).
Cytena – Jonas Schoendube (CEO).
Cellink – Erik Gatenholm (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• DACH
• Healthcare
• High-Tech Gründerfonds
• Venture
• Germany
• Trade sale